Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 3/20 | 0.70 |
| ▸ | HTT | P42858 | 5/20 | 0.45 |
| ▸ | LMNA | P02545 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | TSHR | P16473 | 4/20 | 0.45 |
| ▸ | USP2 | O75604 | 4/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 2/20 | 0.38 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | AKT1 | P31749 | 1/20 | 0.37 |
| ▸ | AKT2 | P31751 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23314242 | 1.00 | OGA (0.70) | OGAHTTLMNAALDH1A1TSHR | |
| SCHEMBL24283127 | 0.84 | OGA (0.49) | OGAHTTLMNAALDH1A1TSHR | |
| SCHEMBL23314236 | 0.83 | OGA (0.70) | OGAHTTLMNAALDH1A1TSHR | |
| SCHEMBL23282517 | 0.82 | OGA (1.00) | OGA | |
| SCHEMBL23282494 | 0.82 | OGA (1.00) | OGA | |
| SCHEMBL23282495 | 0.82 | OGA (1.00) | OGA | |
| SCHEMBL23282532 | 0.82 | OGA (1.00) | OGA | |
| SCHEMBL23282550 | 0.82 | OGA (1.00) | OGA | |
| SCHEMBL23282496 | 0.82 | OGA (1.00) | OGA | |
| SCHEMBL23282515 | 0.82 | OGA (1.00) | OGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3419972-B1 | GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2023-07-26 | — | — | EP | disclosed |
| US-20210186958-A1 | GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2021-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210186958-A1 | GLYCOSIDASE INHIBITORS | ENGASE, GAA, GLA | OGA 73/4885HTT 315/4885LMNA 493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.